摘要
为观察鼻敏康合剂对变应性鼻炎(allergic rhinitis,AR)大鼠鼻黏膜病理及水通道蛋白1(aquaporin 1,AQP1)表达的影响,采用卵清蛋白(ovalbumin,OVA)致敏法建立SD大鼠AR模型,将造模成功的AR大鼠随机分为模型组、西药组、鼻敏康合剂2.53 g/kg组、鼻敏康合剂5.06 g/kg组和鼻敏康合剂10.12 g/kg组,另设空白组。西药组和鼻敏康合剂各剂量组每天灌胃治疗2次,空白组和模型组给予等量生理盐水,连续14 d。观察各组大鼠行为学改变;H-E染色法观察鼻黏膜病理、嗜酸性粒细胞(eosinophil,EOS)数量;免疫组化、ELISA、qRT-PCR检测AQP1蛋白及mRNA表达。结果显示,与空白组比较,模型组大鼠行为学积分显著升高(P<0.05),鼻黏膜组织结构紊乱、重度增生、变性,鼻黏膜EOS数量显著增加(P<0.05),AQP1蛋白及mRNA表达水平显著上调(P<0.05)。与模型组比较,鼻敏康合剂各剂量组大鼠行为学积分显著降低(P<0.05),鼻黏膜组织结构相对整齐,EOS数量下降(P<0.05),AQP1蛋白及mRNA表达水平下调(P<0.05)。该研究提示,鼻敏康合剂可通过下调AQP1表达促进鼻黏膜修复,从而对AR大鼠起到治疗作用。
This study aims to evaluate the effects of Biminkang Formula on nasal mucosa pathology and aquaporin 1(AQP1)expression level in allergic rhinitis(AR)rats.AR rat model was successfully established by ovalbumin(OVA)sensitization in SD rats.AR rats were then randomly divided into control group,untreated AR model group,Western medicine treated group and Biminkang Formula treated groups(2.53,5.06,10.12 g/kg).The Western medicine and Biminkang Formula were administrated to rats by gavaging twice a day for 14 consecutive days,while the control and untreated AR model groups were given the same amount of saline.Behavior changes were observed in each group of rats.Nasal mucosa pathology and eosinophil(EOS)number were evaluated by H-E staining;the protein and mRNA level of AQP1 were measured by immunohistochemistry,ELISA and qRT-PCR,respectively.The results showed that compared with the control group,the behavioral scores of the AR model group were significantly increased(P<0.05);the nasal mucosal tissue structure was severely disordered,characterized by proliferation and degeneration;the number of nasal mucosa EOS was significantly increased(P<0.05),and the expression of AQP1 protein and mRNA were significantly up-regulated(P<0.05).Compared to the untreated AR model group,the Biminkang Formula treated group showed significantly reduced behavioral scores(P<0.05),improved nasal mucosal tissue structure,decreased number of EOS(P<0.05),and down-regulated expression of AQP1 protein and mRNA(P<0.05).Taken together,the results suggest that Biminkang Formula promotes the repair of nasal mucosa,possibly by down-regulating AQP1 expression.Therefore,it is a promising therapy for AR.
作者
杜启雪
孟伟
王仁忠
DU Qi-xue;MENG Wei;WANG Ren-zhong(Otorhinolaryngology,Jinan Municipal Hospital of Traditional Chinese Medicine,Jinan 250000,China;First School of Clinical Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250000,China;Otorhinolaryngology,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250000,China)
出处
《现代免疫学》
CAS
北大核心
2022年第4期286-291,共6页
Current Immunology
基金
国家自然科学基金(81974580)。
